linjc16/ctgov huggingface dataset:
SD-OCT Guided Treatment of Fungal Chorioretinitis

Study Overview
=================
Brief Summary
-----------------
Fungal Chorioretinitis is a vision threatening condition.The investigators evaluate the efficacy of SD-OCT role in the treatment

Detailed Description
-----------------
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination and SD-OCT was done.Procedure included oral fluconazole treatment 1 tablet once for 14 days

Official Title
-----------------
Outcome of SD-OCT Guided Oral Anti-fungal Treatment of Fungal Chorioretinitis

Conditions
-----------------
Fungal Retinitis

Intervention / Treatment
-----------------
* Drug: Fluconazole 150 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - fungal chorioretinitis Exclusion Criteria: vitritis other macular lesion macular scar

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Fluconazole 150 mg|fluconazole 150 MG once daily for 14 days|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best corrected visual acuity (BCVA) | Change in BCVA in LOG MARS(logarithm minimum angle of resolution | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| optical coherence tomography (OCT) foveal thickness | change in foveal thickness measured in micrometer | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fungal, chorioretinitis, OCT
11C-acetate for Treatment Response After Radiotherapy for HCC

Study Overview
=================
Brief Summary
-----------------
It is thought that PET of the abdomen with 11C Acetate will provide new information regarding whether or not patient's have benefited from radiotherapy. To test this theory, the project will evaluate the potential of 11C acetate to serve as an earlier and/or better signal of treatment success.

Official Title
-----------------
Feasibility of 11C-acetate in the Monitoring of Treatment Response Following Radiotherapy in Patients With Hepatocellular Carcinoma

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Drug: 11C-Acetate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 years of age Subject is willing to participate in the study and has signed the study informed consent Subject is available and willing to comply with the protocol evaluations Diagnosed hepatocellular carcinoma confined to a single lobe of the liver if undergoing 90Y radioembolization Diagnosed hepatocellular carcinoma confined to the liver if undergoing Stereotactic Body Radiation Therapy (SBRT) Under consideration for 90Y radioembolization or Stereotactic Body Radiation Therapy (SBRT) Exclusion Criteria: Pregnant or planning to become pregnant within the next 12 months or breast-feeding GFR < 45 Life expectancy < 6 months Claustrophobic and cannot tolerate imaging procedures Weigh > 350 lb (upper weight limit of scanner beds) Special vulnerabilities (e.g. fetuses, neonatales, pregnant women, children, prisoners, institutionalized individuals).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Radiotherapy treatment monitoring of hepatocellular carcinoma<br>All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points. | Drug: 11C-Acetate<br>* The 11C-Acetate radiopharmaceutical will be administered intravenously at a dose of 20-40 mCi (0.74-1.5 GBq). There will be a total of three 11C-acetate radiopharmaceutical administrations for each patient<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To Compare Changes in 11C-acetate Uptake at One and Three Months Following Radiotherapy With Pre-treatment Uptake of 11C-acetate | The single patient enrolled in the trial showed no uptake in the liver tumor on the pretreatment scan and was dropped from the trial. | At three months |
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.

Official Title
-----------------
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Conditions
-----------------
Involutional Osteoporosis

Intervention / Treatment
-----------------
* Drug: Minodronic acid hydrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who was included in study ONO-5920-02 and completed the medication for two years Other inclusion criteria as specified in the study protocol Exclusion Criteria: Patients judged to be unsuitable by safety evaluation as clinical trial subjects by the investigator Patients having secondary osteoporosis or another condition that presents low bone mass Other exclusion criteria as specified in the study protocol

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Minodronic acid hydrate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New fragility vertebral fracture |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New clinical fracture, biochemical markers of bone turnover, height, mean bone mineral density of the lumbar spine (L2-4 BMD), lower back pain. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ONO-5920, osteoporosis, bisphosphonate
Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment

Study Overview
=================
Brief Summary
-----------------
A long-term 0.03% tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis, and prevent, delay, and reduce flares.

Official Title
-----------------
Clinical Study on Tacrolimus Ointment Over the Long-term. CONTROL Study - Children

Conditions
-----------------
Dermatitis, Atopic

Intervention / Treatment
-----------------
* Drug: tacrolimus ointment
* Drug: Placebo ointment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patient of any ethnic group Patient was at least 2-15 years old and suffered from mild to severe atopic dermatitis (Rajka/Langeland score of at least 3) Exclusion Criteria: Patient had a genetic epidermal barrier defect such as Netherton's syndrome or generalised erythroderma Patient had a clinically significant skin infection on the affected (and to be treated) area

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: tacrolimus ointment<br>* Topical application<br>* Other names: FK506 ointment;|
| Placebo Comparator: 2<br> | Drug: Placebo ointment<br>* Topical application<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of exacerbations of atopic dermatitis requiring intervention. |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to first exacerbation requiring intervention; exacerbation treatment days, periods and time to first exacerbation; physician and patient assessment of affected area, treatment response; quality of life; global response. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dermatitis, atopic, Tacrolimus, Child, treatment outcomes
Sundt™ Carotid Shunt Retrospective Post Market Clinical Follow-up Study (PMCF)

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to retrospectively investigate the safety and efficacy of the Integra Sundt™ carotid shunt during endarterectomy procedures.

Official Title
-----------------
Sundt™ Carotid Shunt Retrospective Post Market Clinical Follow-up Study (PMCF)

Conditions
-----------------
Carotid Artery Stenosis

Intervention / Treatment
-----------------
* Device: Sundt carotid shunt


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between the ages of 18-80 years old Have undergone carotid endarterectomy with any Integra Sundt™ carotid shunt on or before date of study initiation Availability of records on post-operative imaging of the carotid artery either by carotid duplex ultrasound or angiogram Exclusion Criteria: Insertion of a carotid shunt at the site of an infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sundt Carotid Shunt<br>Subject has undergone a endarterectomy procedure with the use of the Sundt Carotid Shunt. | Device: Sundt carotid shunt<br>* The Integra Sundt™ carotid shunts are indicated for temporary carotid artery bypass during carotid endarterectomy procedures to help protect the cerebral hemispheres from ischemia during the period of carotid artery occlusion.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of Injury to the Artery or Cerebral Ischemia Secondary to Shunt Placement and Removal | Number of participants with injury to the artery or cerebral ischemia secondary to shunt placement and removal | up to 60 days post-procedure |
Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial.

Study Overview
=================
Brief Summary
-----------------
This study evaluates the effects of different therapies in ovulation induction in Intrauterine Insemination Cycles.

Conditions
-----------------
Female Infertility

Intervention / Treatment
-----------------
* Drug: Meropur 150 a day
* Drug: Gonal-f 150 plus Luveris 150


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with story of infertility sine causa and mild-moderate male factor regular ovulatory menstrual cycles BMI ≤27 kg/m2 normal day 3 hormonal pattern bilateral tubal patency Exclusion Criteria: mono/bilateral tubal occlusion, severe male factor polycystic ovarian syndrome or any systemic disease or endocrine or metabolic abnormalities pelvic inflammatory disease endometriosis sexual organ malformations neoplasms or breast pathology incompatible with gonadotropin stimulation.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 41 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: HP-hMG<br> | Drug: Meropur 150 a day<br>* one subcutaneous injection a day<br>|
| Active Comparator: rFSH plus rLH<br> | Drug: Gonal-f 150 plus Luveris 150<br>* one subcutaneous injection a day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ongoing pregnancy rate |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of cancelled cycles for low or no response, the number of interrupted cycles for high risk of OHSS and multiple pregnancies |  | 30 days |
Family Based Treatment of Early Childhood Obsessive Compulsive Disorder

Study Overview
=================
Brief Summary
-----------------
This study will evaluate a treatment program for young children with Obsessive Compulsive Disorder (OCD) and their families.

Detailed Description
-----------------
Childhood onset OCD is a serious condition that may be a predictor of illness in adulthood. To date, no OCD psychotherapy trials have specifically focused on early childhood. Development of interventions for childhood onset OCD that address both developmental considerations and familial relationships is necessary. Participants are randomly assigned to receive 12 sessions of either Cognitive Behavioral Therapy (CBT) or Relaxation Training (RT) over the course of 14 weeks. The CBT treatment is designed to lessen anxiety by addressing specific OCD symptoms. The relaxation intervention addresses generalized feelings of anxiety with the expectation that OCD symptoms may benefit indirectly. The clarity, completeness, acceptability, and feasibility of both interventions is assessed. A 3-month post-treatment follow-up is also conducted.

Official Title
-----------------
Family Based Treatment of Early Childhood OCD

Conditions
-----------------
Obsessive-Compulsive Disorder

Intervention / Treatment
-----------------
* Behavioral: Cognitive Behavioral Therapy (CBT)
* Behavioral: Relaxation Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obsessive Compulsive Disorder (OCD)

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Cognitive Behavioral Therapy (CBT)|nan|
|Behavioral: Relaxation Training|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex

Study Overview
=================
Brief Summary
-----------------
To determine the safety profile and maximum tolerated dose (MTD) of recombinant soluble human CD4 (rCD4) therapy in patients with AIDS or AIDS related complex (ARC). To obtain a preliminary indication of the antiviral effects of rCD4 in patients with AIDS and ARC. To measure steady state serum levels of rCD4 following continuous infusion therapy.

Official Title
-----------------
A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: CD4 Antigens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: HIV-1 seropositivity. Diagnosis of AIDS or AIDS related complex (ARC). Failure to tolerate or respond to zidovudine (AZT) or decided to decline AZT therapy. The ability to sign a written informed consent form prior to treatment. A willingness to abstain from all other experimental therapy for HIV infection during the entire study period. A life expectancy of at least 3 months. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Serious active opportunistic infections. Malignancies other than Kaposi's sarcoma. Concurrent Medication: Excluded: Zidovudine (AZT). Corticosteroids. Nonsteroidal anti-inflammatory agents (NSAI). Other experimental therapy. Patients with the following are excluded: Serious active opportunistic infections. Malignancies other than Kaposi's sarcoma. Prior Medication: Excluded within 3 weeks of study entry: Zidovudine (AZT). Chemotherapy. Immunomodulators. Other experimental therapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: CD4 Antigens|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acquired Immunodeficiency Syndrome, Antigens, CD4, AIDS-Related Complex
Smoking Cessation in Patients After Coronary Angiography

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES The goal of this study is to evaluate the self-achieved smoking cessation supported with cytisine smoking cessation and its' on platelet aggregation and prothrombotic state in patients after coronary angiography and PCI. BACKGROUND Cigarette smoking is a major risk factor of coronary artery disease (CAD). Smoking cessation is one of the most cost-effective intervention in lifestyle. Self-reported rates of smoking cessation are reasonably low. Cytisine is promising drug in support of smoking cessation. Smoking affects various components leading to arterial thrombosis, and the effect of smoking cessation on prothrombotic state and platelet aggregation is still under investigation GOAL To assess rates of smoking cessation in patients after coronary angiography and PCI and factors influencing success in smoking cessation To assess feasibility, safety and efficacy of cytisine in smoking patients To assess effect of smoking cessation on platelet aggregation in patients treated with clopidogrel and on prothrombotic state. METHODS A prospective nonrandomized observational study of patients after coronary angiography.

Official Title
-----------------
Smoking Cessation in Patients After Coronary Angiography - Self-achieved and Supported With Cytisine and Its' Effect on Platelet Aggregation

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients after coronary angiography or PCI, Aged 18 years or older, Smoking at least 10 cigarettes a day Exclusion Criteria: • Pregnancy Criteria may vary in substudies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelet aggregation in patient treated with clopidogrel after smoking cessation | Platelet reactivity measured with PRU | 30-days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prothrombotic state | Various biomarkers | 30-days | 
| Cotinine | Changes in concentration of cotinine | 30-days | 
| Thrombin potential | Assessment of endogenous thrombin potential | 30-day | 
| Thrombomodulin | Changes of thrombomodulin concentration | 30-days | 
| PAI-1 | Changes of PAI-1 concentration | 30-days | 
| P-selectin | Changes of p-selectin concentration | 30-days | 
| PF-4 | Changes of PF-4 concentration | 30-days | 
| Thromboglobulin | Changes of thromboglobulin concentration | 30-days |
Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia

Study Overview
=================
Brief Summary
-----------------
The present study examined the effects of Methyldopa on uterine artery diameter, uterine artery blood flow, umbilical artery and fetal middle-cerebral artery in patients with Preeclampsia, using Doppler ultrasound.

Conditions
-----------------
Pregnant Women With Mild Preeclampsia

Intervention / Treatment
-----------------
* Drug: Methyldopa
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
They met the inclusion criteria, If they had over 25 weeks of gestational age, no history of chronic hypertension, no diabetes mellitus, no chronic systemic diseases, no collagen vascular diseases and antiphospholipid syndromes, no use of antihypertensive drugs and BMI higher than 19 and lower than 30 (kg/m2).
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Methyldopa<br>In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days. | Drug: Methyldopa<br> <br> |
| Placebo Comparator: placebo<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Doppler indices | In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.Before and after drug use, Doppler ultrasound test was done by a radiology specialist not informed of patients grouping. Also, pulsatility index, resistance index, systolic/diastolic blood flow ratios of uterine artery, umbilical artery and middle-cerebral artery were evaluated. Registered for all patients, age, BMI, gestational week and the number of pregnancies were among other examined variables. Doppler indices of examined arteries in studied groups were evaluated by color Doppler ultrasound of model Hitachi 3/6 MHz. | 7 days |